Table 1.
Patient characteristics, CO-RADS classification, and extra-thoracic sites with increased FDG uptake during the pandemic
| Sex | Age (year) | Disease | Phase | Symptoms | Treatment | CO-RADS | Extra-thoracic sites with FDG uptake | |
|---|---|---|---|---|---|---|---|---|
| 1 | M | 84 | Colon cancer | Staging | None | None | 2 | Liver |
| 2 | F | 60 | Breast cancer | Follow-up | None | Chemotherapy, surgery | 3 | Local recurrence, axillary LN, thyroid |
| 3 | M | 75 | Lung cancer | Staging | Cough, dyspnea | Immunosuppressive therapy for kidney transplantation | 2 | None |
| 4 | M | 64 | Rectal cancer | Follow-up | None | Chemotherapy | 3 | Mediastinal LN |
| 5 | M | 90 | Primary tumor of unknown origin | Diagnosis | Cough, dyspnea, skin rash | None | 3 | None |
| 6 | M | 51 | Thyroid cancer | Follow-up | None | Targeted therapy | 3 | Mediastinal LN, liver |
| 7 | M | 73 | Suspected lymphoma | Diagnosis | Fever | None | 2 | Neck and mediastinal LN, skin, adrenal glands |
| 8 | F | 77 | Non-Hodgkin lymphoma | Follow-up | None | Chemotherapy | 3 | None |
| 9 | F | 61 | Suspected paraneoplastic syndrome | Diagnosis | Fever, neurological symptoms | None | 3 | Muscle |
| 10 | F | 28 | Suspected paraneoplastic syndrome | Diagnosis | Neurological symptoms | None | 3 | Ovary, rectum |
| 11 | M | 36 | Neuroendocrine tumor | Diagnosis | None | None | 3 | Pancreas, mesenteric and inguinal LN |
| 12 | M | 80 | Laryngeal cancer | Follow-up | Cough, dyspnea | None | 5 | None |
| 13 | F | 78 | Breast cancer | Follow-up | None | Chemotherapy | 3 | Adrenal gland |
| 14 | F | 40 | Breast cancer | Follow-up | None | Chemotherapy | 3 | None |
| 15 | F | 60 | Lung cancer | Follow-up | None | Immunotherapy | 2 | Neck and axillary LN, parotid |
| 16 | M | 25 | Hodgkin lymphoma | Follow-up | None | Chemotherapy, radiation therapy | 4 | None |
| 17 | M | 20 | Hodgkin lymphoma | Follow-up | None | Chemotherapy | 3 | Neck LN, bone |
| 18 | M | 56 | Non-Hodgkin lymphoma | Follow-up | None | Chemotherapy | 4 | None |
| 19 | F | 61 | Non-Hodgkin lymphoma | Follow-up | Skin rash | Chemotherapy | 1 | Mediastinal LN |
| 20 | F | 73 | Non-Hodgkin lymphoma | Follow-up | None | Chemotherapy | 3 | None |
| 21 | F | 73 | Multiple myeloma | Follow-up | Cough, dyspnea | Chemotherapy | 2 | Neck and mediastinal LN, bone, adrenal glands |
| 22 | M | 63 | Multiple myeloma | Follow-up | None | Chemotherapy | 4 | Bone |
| 23 | F | 61 | Neuroendocrine tumor | Follow-up | None | None | 3 | Liver, mesenteric LN |
| 24 | M | 73 | Endocarditis | Diagnosis | Cough, dyspnea | None | 3 | Mediastinal LN, bone |
| 25 | M | 92 | Fever of unknown origin | Diagnosis | Fever | None | 3 | Mediastinal LN, colon |
| 26 | M | 65 | Prothesis infection | Diagnosis | Fever | None | 2 | Bone |
F, female; LN, lymph node uptake; M, male